EMA Authorised: Takhzyro (lanadelumab) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

EMA has authorised Takhzyro (lanadelumab) by Takeda for hereditary angioedema with accelerated assessment and orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Takhzyro (lanadelumab)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 28/05/2026. Orphan medicine. Accelerated assessment